Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
|Videos|October 19, 2021
AMCP Nexus 2021: Jane F. Barlow, M.D., M.P.H., MBA, MIT Center for Biomedical Innovation, Addresses Gene, Cell Therapy and Needed Adjustments of High Costs for Payment Models
Author(s)Peter Wehrwein
Barlow spoke at AMCP Nexus about gene and cell therapy and about how payment models need to adjust to account for their high initial cost and their durable — in some cases lifetime — effects.
Advertisement
Advertisement
Related to this article
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
When the referral isn't the finish line: Making SDOH programs actually close care gaps
3
Fewer than 1 in 5 young patients with first-episode psychosis adhere to antipsychotics
4
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
5